HCV infection is the underlying cause for chronic Hepatitis C (CHC), liver cirrhosis, and liver cancer or hepatocellular carcinoma (HCC). In 2019, over 2,90,000 people died of HCV-related diseases. Recent medical advancement made a new breakthrough treatment available for patients with hepatitis C. DAAs that block replication of HCV has dramatically transformed the treatment approach with around 90% effective anti-viral response rates. However, it is unclear whether DAAs impact the severity of disease burden caused by liver fibrosis.
Dupilumab Cuts Lung Inflammation, Breaks Up Mucus Plugs in Asthma Patients
WASHINGTON — Dupilumab (Dupixent) reduced airway inflammation and increased lung capacity in patients with uncontrolled, moderate-to-severe asthma, while also reducing troublesome mucus plugs, a multinational
February 27, 2024